No Data
No Data
Strong Buy Rating for Omeros Corporation Driven by Promising Narsoplimab Prospects and Strategic Advancements
Earnings Preview: Omeros to Report Financial Results Post-market on March 31
Omeros Analyst Ratings
Omeros Announces Phase 3 Trials For Zaltenibart In PNH With Data Expected In Q4 2026; 120 Sites In 30 Countries Activated; Focus On Intravascular And Extravascular Hemolysis With 8-Week Dosing
Omeros Provides Update on Zaltenibart Trial
Express News | Omeros Corp - No Safety Signal of Concern Has Been Observed With Zaltenibart